SG10201604757RA - Dosing regimens for the treatment of fabry disease - Google Patents
Dosing regimens for the treatment of fabry diseaseInfo
- Publication number
- SG10201604757RA SG10201604757RA SG10201604757RA SG10201604757RA SG10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA SG 10201604757R A SG10201604757R A SG 10201604757RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- dosing regimens
- fabry disease
- fabry
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01062—Glycosylceramidase (3.2.1.62)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451798P | 2011-03-11 | 2011-03-11 | |
| US201161578201P | 2011-12-20 | 2011-12-20 | |
| US201261596165P | 2012-02-07 | 2012-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201604757RA true SG10201604757RA (en) | 2016-08-30 |
Family
ID=46831259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201604757RA SG10201604757RA (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
| SG2013067954A SG193379A1 (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013067954A SG193379A1 (en) | 2011-03-11 | 2012-03-08 | Dosing regimens for the treatment of fabry disease |
Country Status (16)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4541418A3 (en) | 2006-05-16 | 2025-07-09 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| HUE042882T2 (hu) | 2008-02-12 | 2019-07-29 | Amicus Therapeutics Inc | Eljárás betegségek farmakológiai chaperonnal történõ kezelésére adott válasz elõrejelzésére |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| KR102494631B1 (ko) | 2013-03-11 | 2023-02-06 | 젠자임 코포레이션 | 당조작을 통한 부위-특이적 항체-약물 접합 |
| AU2015216909B2 (en) * | 2014-02-17 | 2017-07-20 | Glaxosmithkline Intellectual Property Development Limited | Microbiological process |
| AU2015231307B2 (en) | 2014-03-19 | 2021-01-28 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| US9675627B2 (en) * | 2014-04-14 | 2017-06-13 | Amicus Therapeutics, Inc. | Dosing regimens for treating and/or preventing cerebral amyloidoses |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP7001593B2 (ja) | 2015-08-11 | 2022-01-19 | コグノア， インコーポレイテッド | 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置 |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| KR102004114B1 (ko) * | 2016-03-22 | 2019-07-26 | 아미쿠스 세라퓨틱스, 인코포레이티드 | Ｇｌａ 유전자에 ｇ9331ａ 돌연변이를 갖는 환자에서 파브리 질병의 치료 방법 |
| NZ790449A (en) * | 2016-07-19 | 2025-08-29 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| WO2018090009A1 (en) | 2016-11-14 | 2018-05-17 | Cognoa, Inc. | Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability |
| GB2575740A (en) * | 2017-02-09 | 2020-01-22 | Congoa Inc | Platform and system for digital personalized medicine |
| US10251873B2 (en) | 2017-05-30 | 2019-04-09 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| ES2970419T3 (es) * | 2017-05-30 | 2024-05-28 | Amicus Therapeutics Inc | Migalastat para el tratamiento de pacientes de Fabry que tienen disfunción renal |
| JP7066157B2 (ja) | 2017-06-14 | 2022-05-13 | 学校法人 明治薬科大学 | ファブリー病治療用医薬の組合せ物及びその利用 |
| JP7555818B2 (ja) | 2018-02-06 | 2024-09-25 | アミカス セラピューティックス インコーポレイテッド | 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用 |
| EP4285991A3 (en) * | 2018-08-20 | 2024-02-21 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| KR102643554B1 (ko) | 2019-03-22 | 2024-03-04 | 코그노아, 인크. | 개인 맞춤식 디지털 치료 방법 및 디바이스 |
| MA55529A (fr) | 2019-04-03 | 2022-02-09 | Genzyme Corp | Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite |
| EA202290024A1 (ru) * | 2019-06-11 | 2022-03-14 | Амикус Терапьютикс, Инк. | Способы лечения болезни фабри у пациентов с почечной недостаточностью |
| EP3984538A3 (en) | 2019-08-07 | 2022-08-03 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having a mutation in the gla gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| US20240197706A1 (en) * | 2022-12-13 | 2024-06-20 | Amicus Therapeutics, Inc. | Methods of improving the pharmacokinetics of migalastat |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551177A (en) * | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| BRPI0407001A (pt) * | 2003-01-31 | 2006-01-10 | Sinai School Medicine | Método para aumentar a estabilidade de uma proteìna purificada, uso de uma proteìna ligante sìtio-especìfica ativa, método para aumentar a produção de uma proteìna recombinante e composição farmacêutica |
| US7879354B2 (en) * | 2004-01-13 | 2011-02-01 | Mcneil-Ppc, Inc. | Rapidly disintegrating gelatinous coated tablets |
| CN100457106C (zh) * | 2005-06-15 | 2009-02-04 | 同济大学 | 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用 |
| EP4541418A3 (en) * | 2006-05-16 | 2025-07-09 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for fabry disease |
| MX2009010557A (es) * | 2007-03-30 | 2009-11-19 | Amicus Therapeutics Inc | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. |
| CA2685332A1 (en) * | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| WO2009032171A1 (en) * | 2007-08-29 | 2009-03-12 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of alpha-galatosidase a |
-
2012
- 2012-03-08 ES ES12758017T patent/ES2807502T3/es active Active
- 2012-03-08 AU AU2012229330A patent/AU2012229330B2/en active Active
- 2012-03-08 SG SG10201604757RA patent/SG10201604757RA/en unknown
- 2012-03-08 JP JP2013557862A patent/JP2014528901A/ja active Pending
- 2012-03-08 US US14/004,335 patent/US20140219986A1/en not_active Abandoned
- 2012-03-08 KR KR1020137026394A patent/KR20140011367A/ko not_active Ceased
- 2012-03-08 SG SG2013067954A patent/SG193379A1/en unknown
- 2012-03-08 CN CN201280021877.8A patent/CN103974619B/zh active Active
- 2012-03-08 CA CA2829947A patent/CA2829947C/en active Active
- 2012-03-08 EP EP20160164.8A patent/EP3698792A1/en active Pending
- 2012-03-08 MX MX2013010446A patent/MX2013010446A/es unknown
- 2012-03-08 EP EP12758017.3A patent/EP2683382B1/en active Active
- 2012-03-08 EA EA201301018A patent/EA031874B1/ru not_active IP Right Cessation
- 2012-03-08 CN CN201611235913.7A patent/CN107088225A/zh active Pending
- 2012-03-08 WO PCT/US2012/028260 patent/WO2012125402A2/en active Application Filing
- 2012-03-12 TW TW105118425A patent/TWI624259B/zh not_active IP Right Cessation
- 2012-03-12 TW TW106126844A patent/TW201740945A/zh unknown
- 2012-03-12 TW TW101108345A patent/TWI624258B/zh not_active IP Right Cessation
-
2013
- 2013-09-09 ZA ZA2013/06735A patent/ZA201306735B/en unknown
- 2013-09-10 CL CL2013002601A patent/CL2013002601A1/es unknown
-
2016
- 2016-06-28 AU AU2016204445A patent/AU2016204445B2/en active Active
-
2017
- 2017-03-01 JP JP2017038469A patent/JP2017132780A/ja active Pending
- 2017-10-12 US US15/782,431 patent/US20180153999A1/en not_active Abandoned
-
2018
- 2018-02-23 HK HK18102615.1A patent/HK1242998A1/zh unknown
- 2018-03-07 AU AU2018201637A patent/AU2018201637A1/en not_active Abandoned
-
2019
- 2019-10-10 JP JP2019186952A patent/JP2020033360A/ja active Pending
-
2020
- 2020-03-02 US US16/806,404 patent/US20200268890A1/en not_active Abandoned
- 2020-03-09 AU AU2020201715A patent/AU2020201715A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018456A patent/JP2021098697A/ja not_active Withdrawn
-
2022
- 2022-05-05 AU AU2022203011A patent/AU2022203011A1/en not_active Abandoned
-
2023
- 2023-03-22 JP JP2023045001A patent/JP2023093448A/ja active Pending
- 2023-07-17 US US18/222,745 patent/US20240115708A1/en active Pending
-
2024
- 2024-07-31 AU AU2024205251A patent/AU2024205251A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201306735B (en) | Dosing regimens for the treatment of fabry disease | |
| RS61598B1 (sr) | Režimi doziranja za tretman pompeove bolesti | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| IL229254A0 (en) | Therapeutic antibodies | |
| EP2776441A4 (en) | TREATMENT METHOD WITH MULTIPLE PHARMACEUTICAL AGENTS | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| EP2704712A4 (en) | ISOXAZOLINES AS THERAPEUTIC AGENTS | |
| ZA201306613B (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| EP2700429A4 (en) | DRUG SOLUTION APPLICATOR | |
| ZA201307760B (en) | Treatment regimens | |
| IL234796B (en) | Compounds for the treatment of diseases related to ischemia-reperfusion | |
| ZA201308176B (en) | Therapeutic treatment | |
| HK40112795A (en) | Dosing regimens for the treatment of pompe disease | |
| HK1192488A (zh) | 用作治疗法布瑞氏症的给药方案 | |
| GB201106981D0 (en) | Compounds for the treatment of clostridium difficle-associated disease | |
| IL232294A0 (en) | Preparations for the treatment of diabetes | |
| GB201110895D0 (en) | Therapeutic use | |
| GB201117026D0 (en) | Non-invasive monitor | |
| GB201115558D0 (en) | Therapeutic agents | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201101128D0 (en) | Therapeutic agents | |
| HUE041625T2 (hu) | Terápiás ellenanyagok | |
| GB201104632D0 (en) | Use of medicament |